Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir
- PMID: 15194788
- PMCID: PMC421656
- DOI: 10.1128/JVI.78.13.7124-7130.2004
Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir
Abstract
Previous drug selection experiments resulted in the isolation of a human cytomegalovirus (CMV) UL97 phosphotransferase mutant resistant to the benzimidazole compound maribavir (1263W94), reflecting the anti-UL97 effect of this drug. Three other CMV strains were plaque purified during these experiments. These strains showed lower-grade resistance to maribavir than the UL97 mutant. Extensive DNA sequence analyses showed no changes from the baseline strain AD169 in UL97, the genes involved in DNA replication, and most structural proteins. However, changes were identified in UL27 where each strain contained a different mutation (R233S, W362R, or a combination of A406V and a stop at codon 415). The mutation at codon 415 is predicted to truncate the expressed UL27 protein by 193 codons (32% of UL27) with a loss of nuclear localization. The expression of full-length UL27 as a green fluorescent fusion protein in uninfected fibroblasts resulted in nuclear and nucleolar fluorescence, whereas cytoplasmic localization was observed when codons 1 to 415 were similarly expressed. Viable UL27 deletion mutants were created by recombination and showed slight growth attenuation and maribavir resistance in cell culture. Marker transfer experiments confirmed that UL27 mutations conferred maribavir resistance. The UL27 sequence was well conserved in a sample of 16 diverse clinical isolates. Mutation in UL27, a betaherpesvirus-specific early gene of unknown biological function, may adapt the virus for growth in the absence of UL97 activity.
Figures






Similar articles
-
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.Antimicrob Agents Chemother. 2009 Jan;53(1):81-5. doi: 10.1128/AAC.01177-08. Epub 2008 Nov 3. Antimicrob Agents Chemother. 2009. PMID: 18981262 Free PMC article.
-
Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.Antiviral Res. 2012 Aug;95(2):88-92. doi: 10.1016/j.antiviral.2012.05.013. Epub 2012 Jun 1. Antiviral Res. 2012. PMID: 22664236 Free PMC article.
-
Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.J Infect Dis. 2007 Jul 1;196(1):91-4. doi: 10.1086/518514. Epub 2007 May 17. J Infect Dis. 2007. PMID: 17538888
-
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.Rev Med Virol. 2008 Jul-Aug;18(4):233-46. doi: 10.1002/rmv.574. Rev Med Virol. 2008. PMID: 18383425 Review.
-
Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.Antiviral Res. 2019 Mar;163:91-105. doi: 10.1016/j.antiviral.2019.01.011. Epub 2019 Jan 25. Antiviral Res. 2019. PMID: 30690043 Review.
Cited by
-
Human Cytomegalovirus (HCMV) Genetic Diversity, Drug Resistance Testing and Prevalence of the Resistance Mutations: A Literature Review.Trop Med Infect Dis. 2024 Feb 15;9(2):49. doi: 10.3390/tropicalmed9020049. Trop Med Infect Dis. 2024. PMID: 38393138 Free PMC article. Review.
-
Identification of lead anti-human cytomegalovirus compounds targeting MAP4K4 via machine learning analysis of kinase inhibitor screening data.PLoS One. 2018 Jul 26;13(7):e0201321. doi: 10.1371/journal.pone.0201321. eCollection 2018. PLoS One. 2018. PMID: 30048526 Free PMC article.
-
Update on new antivirals under development for the treatment of double-stranded DNA virus infections.Clin Pharmacol Ther. 2010 Nov;88(5):610-9. doi: 10.1038/clpt.2010.178. Epub 2010 Sep 29. Clin Pharmacol Ther. 2010. PMID: 20881959 Free PMC article. Review.
-
Anti-CMV therapy, what next? A systematic review.Front Microbiol. 2023 Nov 20;14:1321116. doi: 10.3389/fmicb.2023.1321116. eCollection 2023. Front Microbiol. 2023. PMID: 38053548 Free PMC article. Review.
-
Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus.Ther Clin Risk Manag. 2022 Mar 12;18:223-232. doi: 10.2147/TCRM.S303052. eCollection 2022. Ther Clin Risk Manag. 2022. PMID: 35308097 Free PMC article. Review.
References
-
- Baek M. C., P. M. Krosky, Z. He, and D. M. Coen. 2002. Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase. Importance of the P+5 position. J. Biol. Chem. 277:29593-29599. - PubMed
-
- Biron K. K., R. J. Harvey, S. C. Chamberlain, S. S. Good, A. A. Smith III, M. G. Davis, C. L. Talarico, W. H. Miller, R. Ferris, R. E. Dornsife, S. C. Stanat, J. C. Drach, L. B. Townsend, and G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:2365-2372. - PMC - PubMed
-
- Chou S., N. S. Lurain, K. D. Thompson, R. C. Miner, and W. L. Drew. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188:32-39. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources